

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 October 2023 (19.10.2023)



(10) International Publication Number
WO 2023/201228 A1

(51) International Patent Classification:

C12N 9/78 (2006.01) *A61K 38/51* (2006.01)
A61K 38/50 (2006.01) *A61P 3/00* (2006.01)
A61K 38/00 (2006.01) *C07K 14/00* (2006.01)

(21) International Application Number:

PCT/US2023/065630

(22) International Filing Date:

11 April 2023 (11.04.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/329,867 11 April 2022 (11.04.2022) US

(71) Applicants: **AEGLEA BIOTHERAPEUTICS, INC.**

[US/US]; 805 Las Cimas Parkway, Suite 100, Austin, Texas
78746 (US). **AERASE, INC.** [US/US]; 805 Las Cimas
Parkway, Suite 100, Austin, Texas 78746 (US).

(72) Inventor; and

(71) Applicant: **QUINN, Anthony G.** [US/US]; c/o 805 Las
Cimas Parkway, Suite 100, Austin, Texas 78746 (US).


(74) Agent: **FENG, Shanxi** et al.; 1299 Pennsylvania Av-
enue, NW, Suite 700, Washington, District of Columbia
20004-2400 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: TREATMENT OF ARGINASE 1 DEFICIENCY

Figure 1A



ARG1-D, Arginase 1 Deficiency; IV, intravenous; qw, weekly; R, randomized; SC, subcutaneous.

*Diagnosis through elevated plasma arginine, pathogenic ARG1 variant, or diminished erythrocyte arginase activity.

†Dosing is weekly and, if needed, dose is modified based on plasma arginine levels with maintenance of blinding.

†Blinding will be maintained for the first 8 weeks of the long-term extension.

(57) Abstract: A method of treating Arginase 1 (ARG1) deficiency (ARG1-D) in a subject, comprising administering a pegzilarginase to the subject, wherein the pegzilarginase is a pegylated human arginase 1 comprising a cobalt metal cofactor, and wherein the pegzilarginase is administered weekly at a dose of from about 0.05 mg/kg to about 0.2 mg/kg.

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*